Peto

Peto is a biotechnology company focused on developing novel cancer therapeutics by leveraging the biological insights of Peto's Paradox—the observation that large animals like elephants have unexpectedly low cancer rates despite their size. The company specifically targets the p53 pathway, utilizing elephant-derived genetic insights to create treatments for canine and potentially human cancers. By focusing on comparative oncology, Peto aims to bridge the gap between veterinary and human medicine, starting with high-need indications in dogs such as osteosarcoma and lymphoma. Their approach involves identifying and translating natural cancer-resistance mechanisms into pharmacological interventions.